Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 19/20 | 1.00 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088443 | 0.95 | SERPINE1 (0.90) | SERPINE1SLC6A9SLC6A5 | |
| SCHEMBL7088465 | 0.89 | SERPINE1 (0.80) | SERPINE1 | |
| SCHEMBL7089125 | 0.87 | SERPINE1 (1.00) | SERPINE1SLC6A9SLC6A5 | |
| SCHEMBL7090422 | 0.84 | SERPINE1 (0.73) | SERPINE1 | |
| SCHEMBL7087984 | 0.84 | SERPINE1 (0.73) | SERPINE1 | |
| SCHEMBL7089111 | 0.84 | SERPINE1 (0.72) | SERPINE1SLC6A9SLC6A5 | |
| SCHEMBL7084535 | 0.82 | SERPINE1 (0.69) | SERPINE1 | |
| SCHEMBL7087684 | 0.81 | SERPINE1 (0.68) | SERPINE1SLC6A9SLC6A5 | |
| SCHEMBL7089118 | 0.81 | SERPINE1 (0.68) | SERPINE1SLC6A9SLC6A5 | |
| SCHEMBL7088445 | 0.81 | SERPINE1 (1.00) | SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105574-A1 | PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS | ALCON RESEARCH, LTD. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2296647-A2 | PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS | Alcon Research, Ltd. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009131850-A2 | PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS | ALCON RESEARCH, LTD. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090202524-A1 | PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS | ALCON RESEARCH, LTD. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2003080060-A1 | SUBSTITUTED PIPERAZINE ANTITHROMBOTIC PAI-1 INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202524-A1 | PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885SLC6A9 4624/4885SLC6A5 4615/4885 |
| US-20110105574-A1 | PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885SLC6A9 4624/4885SLC6A5 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.